Free Trial
→ We’ve Entered the Most Bullish Phase of the Cycle (From Crypto Swap Profits) (Ad) Buy DAWN Stock  Free DAWN Stock Alerts

Day One Biopharmaceuticals (DAWN) Financials

Day One Biopharmaceuticals logo
$6.48 0.00 (0.00%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$6.48 +0.00 (+0.02%)
As of 06/24/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Day One Biopharmaceuticals

Annual Income Statements for Day One Biopharmaceuticals

This table shows Day One Biopharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -142 -189 -95
Consolidated Net Income / (Loss)		 -142 -189 -95
Net Income / (Loss) Continuing Operations		 -142 -189 -95
Total Pre-Tax Income 		-142 -189 -88
Total Operating Income		 -147 -206 -217
Total Gross Profit		 0.00 0.00 126
Total Revenue		 0.00 0.00 131
Operating Revenue		 0.00 0.00 131
Total Cost of Revenue		 0.00 0.00 5.28
Operating Cost of Revenue		 0.00 0.00 5.28
Total Operating Expenses		 147 206 343
Selling, General & Admin Expense		 61 76 115
Research & Development Expense		 86 131 228
Total Other Income / (Expense), net		 4.73 17 129
Interest & Investment Income		 4.75 17 128
Other Income / (Expense), net		 -0.02 - 1.22
Income Tax Expense		 0.00 0.00 7.14
Basic Earnings per Share		 ($2.17) ($2.37) ($1.02)
Weighted Average Basic Shares Outstanding		 65.47M 79.77M 93.23M
Diluted Earnings per Share		 ($2.17) ($2.37) ($1.02)
Weighted Average Diluted Shares Outstanding		 65.47M 79.77M 93.23M
Weighted Average Basic & Diluted Shares Outstanding		 73.59M 87.38M 101.35M

Quarterly Income Statements for Day One Biopharmaceuticals

This table shows Day One Biopharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -38 -40 -42 -46 -46 -55 -62 -7.26 73 -99
Consolidated Net Income / (Loss)		 -38 -40 -42 -46 -46 -55 -62 -4.41 37 -66
Net Income / (Loss) Continuing Operations		 -38 -40 -42 -46 -46 -55 -62 -4.41 37 -66
Total Pre-Tax Income 		-38 -40 -42 -46 -46 -55 -62 -2.86 36 -59
Total Operating Income		 -40 -43 -46 -49 -51 -60 -67 -115 30 -65
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 7.49 92 26
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 8.19 94 29
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.71 1.59 2.98
Total Operating Expenses		 40 43 46 49 51 60 67 122 63 92
Selling, General & Admin Expense		 18 17 18 17 18 22 27 30 29 30
Research & Development Expense		 22 26 28 32 33 37 40 92 34 62
Total Other Income / (Expense), net		 1.90 2.63 3.46 3.39 5.29 5.05 4.36 112 6.52 6.09
Interest & Investment Income		 1.90 2.66 3.47 3.41 5.29 5.02 4.37 112 5.32 6.05
Other Income / (Expense), net		 0.01 -0.03 -0.00 -0.02 -0.00 - -0.01 -0.01 1.20 0.04
Basic Earnings per Share		 ($0.53) ($0.56) ($0.59) ($0.61) ($0.54) ($0.63) ($0.72) ($0.05) $0.38 ($0.63)
Weighted Average Basic Shares Outstanding		 71.01M 65.47M 71.97M 74.96M 85.95M 79.77M 86.68M 87.12M 96.62M 93.23M
Diluted Earnings per Share		 ($0.53) ($0.56) ($0.59) ($0.61) ($0.54) ($0.63) ($0.72) ($0.05) $0.38 ($0.63)
Weighted Average Diluted Shares Outstanding		 71.01M 65.47M 71.97M 74.96M 85.95M 79.77M 86.68M 87.12M 96.94M 93.23M
Weighted Average Basic & Diluted Shares Outstanding		 73.55M 73.59M 73.57M 86.97M 87.04M 87.38M 87.39M 87.76M 100.85M 101.35M

Annual Cash Flow Statements for Day One Biopharmaceuticals

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -199 146 -106
Net Cash From Operating Activities		 -110 -147 -78
Net Cash From Continuing Operating Activities		 -110 -147 -78
Net Income / (Loss) Continuing Operations		 -142 -189 -95
Consolidated Net Income / (Loss)		 -142 -189 -95
Depreciation Expense		 0.06 0.04 0.09
Amortization Expense		 -1.56 -9.73 -4.45
Non-Cash Adjustments To Reconcile Net Income		 27 42 -4.74
Changes in Operating Assets and Liabilities, net		 6.56 9.42 26
Net Cash From Investing Activities		 -255 128 -231
Net Cash From Continuing Investing Activities		 -255 128 -231
Purchase of Property, Plant & Equipment		 -0.03 -0.22 -2.17
Acquisitions		 0.00 0.00 -17
Purchase of Investments		 -394 -444 -659
Sale of Property, Plant & Equipment		 0.00 0.00 108
Sale and/or Maturity of Investments		 139 575 394
Other Investing Activities, net		 0.00 -3.00 -55
Net Cash From Financing Activities		 166 164 203
Net Cash From Continuing Financing Activities		 166 164 203
Issuance of Common Equity		 162 163 201
Other Financing Activities, net		 3.65 1.34 2.27
Cash Income Taxes Paid		 0.00 0.00 1.90

Quarterly Cash Flow Statements for Day One Biopharmaceuticals

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -268 -36 -36 140 52 -10 40 -31 183 -298
Net Cash From Operating Activities		 -23 -35 -26 -42 -37 -41 -50 -49 51 -30
Net Cash From Continuing Operating Activities		 -23 -35 -26 -42 -37 -41 -50 -49 51 -30
Net Income / (Loss) Continuing Operations		 -38 -40 -42 -46 -46 -55 -62 -4.41 37 -66
Consolidated Net Income / (Loss)		 -38 -40 -42 -46 -46 -55 -62 -4.41 37 -66
Depreciation Expense		 0.04 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.04
Amortization Expense		 0.13 -1.87 -0.52 -5.17 -2.56 -1.49 -1.20 -0.50 -0.65 -2.10
Non-Cash Adjustments To Reconcile Net Income		 7.55 7.86 9.45 9.48 12 11 13 -95 67 11
Changes in Operating Assets and Liabilities, net		 6.87 -1.22 7.47 -0.88 -0.68 3.50 1.22 51 -52 27
Net Cash From Investing Activities		 -247 -2.21 -11 20 89 30 89 17 -68 -270
Net Cash From Continuing Investing Activities		 -247 -2.21 -11 20 89 30 89 17 -68 -270
Purchase of Property, Plant & Equipment		 -0.00 - -0.03 -0.15 -0.04 -0.01 0.00 -0.03 -0.72 -1.42
Purchase of Investments		 -267 -121 -160 -105 -80 -99 -47 -122 -215 -275
Sale and/or Maturity of Investments		 20 119 149 125 172 130 136 48 203 7.00
Net Cash From Financing Activities		 2.05 1.92 1.18 162 0.12 0.60 0.05 1.30 200 1.85
Net Cash From Continuing Financing Activities		 2.37 1.92 1.18 162 0.12 0.60 0.05 1.30 200 1.85
Issuance of Common Equity		 0.32 0.32 0.00 162 - 0.60 0.00 0.97 199 0.93
Other Financing Activities, net		 2.05 1.60 1.18 0.04 0.12 - 0.05 0.32 0.98 0.92
Cash Income Taxes Paid		 - - - - - - - - - 1.02

Annual Balance Sheets for Day One Biopharmaceuticals

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 349 376 583
Total Current Assets		 348 375 562
Cash & Equivalents		 85 231 125
Short-Term Investments		 257 136 407
Accounts Receivable		 - 0.00 14
Inventories, net		 - 0.00 3.32
Prepaid Expenses		 5.61 8.93 13
Plant, Property, & Equipment, net		 0.02 0.21 2.29
Total Noncurrent Assets		 1.17 0.57 18
Intangible Assets		 - 0.00 16
Other Noncurrent Operating Assets		 1.17 0.57 2.54
Total Liabilities & Shareholders' Equity		 349 376 583
Total Liabilities		 17 30 80
Total Current Liabilities		 17 30 73
Accounts Payable		 0.26 2.58 3.26
Accrued Expenses		 16 27 69
Current Deferred Revenue		 - 0.00 1.55
Other Current Liabilities		 0.41 0.41 0.01
Total Noncurrent Liabilities		 0.41 0.00 6.59
Noncurrent Deferred Revenue		 - 0.00 3.23
Other Noncurrent Operating Liabilities		 0.41 0.00 3.35
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 332 347 503
Total Preferred & Common Equity		 332 347 503
Total Common Equity		 332 347 503
Common Stock		 602 805 1,057
Retained Earnings		 -270 -459 -554
Accumulated Other Comprehensive Income / (Loss)		 -0.07 0.01 0.08

Quarterly Balance Sheets for Day One Biopharmaceuticals

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 382 324 451 414 327 400 601
Total Current Assets		 381 645 450 413 326 383 581
Cash & Equivalents		 121 49 189 241 270 240 423
Short-Term Investments		 253 269 254 164 48 122 136
Accounts Receivable		 - - - - - 9.14 8.70
Inventories, net		 - - - - - 0.15 2.74
Prepaid Expenses		 6.17 4.21 6.90 7.75 8.09 12 11
Plant, Property, & Equipment, net		 0.04 0.07 0.18 0.21 0.19 0.20 0.90
Total Noncurrent Assets		 1.31 1.10 0.79 0.68 0.26 17 19
Intangible Assets		 - - - - - 17 16
Other Noncurrent Operating Assets		 1.31 1.10 0.79 0.68 0.26 0.16 2.69
Total Liabilities & Shareholders' Equity		 382 324 451 414 327 400 601
Total Liabilities		 19 23 25 25 30 94 45
Total Current Liabilities		 18 23 25 24 30 94 40
Accounts Payable		 3.97 4.66 4.57 3.39 4.78 6.44 3.02
Accrued Expenses		 14 18 20 21 25 87 35
Current Deferred Revenue		 - - - - - - 1.46
Other Current Liabilities		 0.46 0.42 0.43 0.44 0.30 0.19 0.08
Total Noncurrent Liabilities		 0.51 0.30 0.19 0.08 0.00 0.00 5.60
Noncurrent Deferred Revenue		 - - - - - - 3.06
Other Noncurrent Operating Liabilities		 0.51 0.30 0.19 0.08 - - 2.54
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 363 300 426 390 297 307 555
Total Preferred & Common Equity		 363 300 426 390 297 307 555
Total Common Equity		 363 300 426 390 297 307 555
Common Stock		 593 612 784 794 818 832 1,044
Retained Earnings		 -230 -312 -358 -404 -521 -525 -488
Accumulated Other Comprehensive Income / (Loss)		 -0.39 0.07 -0.01 -0.01 -0.01 -0.02 -0.01

Annual Metrics And Ratios for Day One Biopharmaceuticals

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -104.56% -45.36% -2.16%
EBIT Growth		 -101.94% -40.25% -4.85%
NOPAT Growth		 -101.96% -40.27% -5.44%
Net Income Growth		 -95.43% -32.87% 49.45%
EPS Growth		 53.03% -9.22% 56.96%
Operating Cash Flow Growth		 -126.36% -33.66% 46.81%
Free Cash Flow Firm Growth		 31.39% -40.37% -6.13%
Invested Capital Growth		 -207.21% -93.62% -46.26%
Revenue Q/Q Growth		 0.00% 0.00% 28.65%
EBITDA Q/Q Growth		 -18.06% -9.31% -8.05%
EBIT Q/Q Growth		 -16.50% -8.83% -2.74%
NOPAT Q/Q Growth		 -16.46% -8.86% -2.75%
Net Income Q/Q Growth		 -14.65% -8.25% -13.29%
EPS Q/Q Growth		 -226.16% -3.04% 0.00%
Operating Cash Flow Q/Q Growth		 -25.24% -4.31% 12.70%
Free Cash Flow Firm Q/Q Growth		 0.00% -5.33% 11.23%
Invested Capital Q/Q Growth		 9.19% -24.49% -892.09%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 95.98%
EBITDA Margin		 0.00% 0.00% -168.05%
Operating Margin		 0.00% 0.00% -165.65%
EBIT Margin		 0.00% 0.00% -164.72%
Profit (Net Income) Margin		 0.00% 0.00% -72.81%
Tax Burden Percent		 100.00% 100.00% 108.09%
Interest Burden Percent		 96.77% 91.68% 40.89%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.37% -55.68% -22.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -45.07%
Return on Assets (ROA)		 0.00% 0.00% -19.92%
Return on Common Equity (ROCE)		 -46.37% -55.68% -22.49%
Return on Equity Simple (ROE_SIMPLE)		 -42.82% -54.52% -18.99%
Net Operating Profit after Tax (NOPAT)		 -103 -144 -152
NOPAT Margin		 0.00% 0.00% -115.96%
Net Nonoperating Expense Percent (NNEP)		 -12.56% -12.61% 12.60%
Return On Investment Capital (ROIC_SIMPLE)		 -30.97% -41.62% -30.25%
Cost of Revenue to Revenue		 0.00% 0.00% 4.02%
SG&A Expenses to Revenue		 0.00% 0.00% 88.02%
R&D to Revenue		 0.00% 0.00% 173.61%
Operating Expenses to Revenue		 0.00% 0.00% 261.63%
Earnings before Interest and Taxes (EBIT)		 -147 -206 -216
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -148 -216 -220
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 4.77 3.67 2.54
Price to Tangible Book Value (P/TBV)		 4.77 3.67 2.62
Price to Revenue (P/Rev)		 0.00 0.00 9.74
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 5.69
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.04 -1.06
Leverage Ratio		 1.04 1.07 1.13
Compound Leverage Factor		 1.01 0.98 0.46
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 54.46 23.43 8.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 20.94 12.72 7.66
Quick Ratio		 20.60 12.42 7.43
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -96 -135 -143
Operating Cash Flow to CapEx		 -422,592.31% -65,559.38% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.27
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 105.22
Accounts Payable Turnover		 0.00 0.00 1.81
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 201.83
Cash Conversion Cycle (CCC)		 0.00 0.00 -201.83
Capital & Investment Metrics		 - - -
Invested Capital		 -10 -20 -29
Invested Capital Turnover		 0.00 0.00 -5.38
Increase / (Decrease) in Invested Capital		 -6.90 -9.58 -9.16
Enterprise Value (EV)		 1,241 904 746
Market Capitalization		 1,583 1,271 1,278
Book Value per Share		 $4.51 $3.98 $4.99
Tangible Book Value per Share		 $4.51 $3.98 $4.83
Total Capital		 332 347 503
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -342 -366 -532
Capital Expenditures (CapEx)		 0.03 0.22 -106
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -21 -43
Debt-free Net Working Capital (DFNWC)		 331 346 489
Net Working Capital (NWC)		 331 346 489
Net Nonoperating Expense (NNE)		 39 45 -57
Net Nonoperating Obligations (NNO)		 -342 -366 -532
Total Depreciation and Amortization (D&A)		 -1.50 -9.70 -4.36
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -32.66%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 372.73%
Net Working Capital to Revenue		 0.00% 0.00% 372.73%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.17) ($2.37) ($1.02)
Adjusted Weighted Average Basic Shares Outstanding		 65.47M 79.77M 93.23M
Adjusted Diluted Earnings per Share		 ($2.17) ($2.37) ($1.02)
Adjusted Weighted Average Diluted Shares Outstanding		 65.47M 79.77M 93.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 73.59M 87.38M 101.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -103 -144 -152
Normalized NOPAT Margin		 0.00% 0.00% -115.96%
Pre Tax Income Margin		 0.00% 0.00% -67.36%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Day One Biopharmaceuticals

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -106.03% -103.62% -67.42% -48.79% -36.59% -36.69% -46.55% -111.82% 155.94% -10.44%
EBIT Growth		 -106.35% -94.72% -65.26% -34.18% -29.61% -39.16% -45.61% -133.04% 159.94% -9.70%
NOPAT Growth		 -106.33% -36.14% -65.26% -34.14% -29.57% -39.24% -45.60% -133.09% 184.32% -9.77%
Net Income Growth		 -96.44% -82.81% -52.78% -25.55% -22.11% -35.91% -47.22% 90.39% 180.25% -20.55%
EPS Growth		 -60.61% -116.82% -22.92% -1.67% -1.89% -12.50% -22.03% 91.80% 170.37% 0.00%
Operating Cash Flow Growth		 -89.95% -168.13% -20.51% -42.45% -59.66% -17.17% -91.38% -15.78% 236.93% 27.47%
Free Cash Flow Firm Growth		 -14.53% 0.00% -1,985.54% -11.06% -95.85% -39.38% 182.15% -91.66% 155.38% -13.98%
Invested Capital Growth		 -2,300.20% -207.21% 9,838.62% -297.54% -41.24% -93.62% -106.99% -228.33% 81.65% -46.26%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,044.54% -68.85%
EBITDA Q/Q Growth		 -8.03% -12.89% -8.88% -17.40% 0.83% -12.97% -14.34% -69.68% 126.19% -323.02%
EBIT Q/Q Growth		 -8.09% -7.76% -7.22% -7.44% -4.41% -15.70% -12.16% -71.94% 126.85% -311.76%
NOPAT Q/Q Growth		 -8.12% -7.67% -7.28% -7.41% -4.43% -15.71% -12.18% -71.95% 137.78% -250.64%
Net Income Q/Q Growth		 -3.46% -6.12% -5.69% -8.19% -0.63% -18.12% -14.49% 92.94% 940.41% -277.43%
EPS Q/Q Growth		 11.67% -5.66% -5.36% -3.39% 11.48% -16.67% -14.29% 93.06% 860.00% -265.79%
Operating Cash Flow Q/Q Growth		 22.07% -52.11% 26.41% -63.29% 12.65% -11.62% -20.20% 1.21% 203.31% -159.13%
Free Cash Flow Firm Q/Q Growth		 18.73% -43.77% -1,376.32% 93.56% -43.31% -2.31% 970.17% -115.02% 141.41% -310.56%
Invested Capital Q/Q Growth		 -166.12% 9.19% 3,077.75% -105.52% 5.45% -24.49% -7.56% -159.34% 94.72% -892.09%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.37% 98.30% 89.79%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,407.54% 32.21% -230.61%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,401.45% 31.61% -223.68%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,401.57% 32.88% -223.54%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -53.80% 39.50% -224.99%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 154.36% 102.44% 110.93%
Interest Burden Percent		 95.23% 93.78% 92.44% 93.09% 89.71% 91.59% 93.46% 2.49% 117.26% 90.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.44% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -37.54% -46.37% -56.01% -40.69% -46.37% -55.68% -69.97% -45.71% -17.84% -22.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -138.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -26.98% 6.61% -61.16%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.04% 7.94% -61.55%
Return on Common Equity (ROCE)		 -37.54% -46.37% -56.01% -40.69% -46.37% -55.68% -69.97% -45.71% -17.84% -22.49%
Return on Equity Simple (ROE_SIMPLE)		 -34.16% 0.00% -52.20% -39.00% -44.79% 0.00% -70.39% -54.60% -15.18% 0.00%
Net Operating Profit after Tax (NOPAT)		 -28 -30 -32 -34 -36 -42 -47 -80 30 -46
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -981.02% 32.38% -156.57%
Net Nonoperating Expense Percent (NNEP)		 -2.98% -3.25% -7.96% -2.72% -2.60% -3.63% -9.99% 18.87% 1.39% -4.45%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.01% - - - -12.02% - - - -9.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.63% 1.70% 10.21%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 368.48% 30.90% 101.80%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,124.34% 35.80% 211.66%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,492.82% 66.70% 313.47%
Earnings before Interest and Taxes (EBIT)		 -40 -43 -46 -49 -51 -60 -67 -115 31 -65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -45 -46 -54 -54 -61 -68 -115 30 -67
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.05 4.77 3.28 2.06 2.74 3.67 4.84 3.93 2.20 2.54
Price to Tangible Book Value (P/TBV)		 4.05 4.77 3.28 2.06 2.74 3.67 4.84 4.15 2.27 2.62
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 147.00 11.99 9.74
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 2.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 102.83 6.51 5.69
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 6.70 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -0.46 -1.03 -1.04 -1.04 -0.53 -1.10 -1.02 -1.06
Leverage Ratio		 1.04 1.04 1.06 1.05 1.06 1.07 1.09 1.16 1.07 1.13
Compound Leverage Factor		 0.99 0.98 0.98 0.97 0.95 0.98 1.02 0.03 1.26 1.02
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 46.95 55.44 25.99 21.00 25.43 24.71 27.09 5.82 16.46 9.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 20.83 20.94 28.22 18.35 16.89 12.72 10.93 4.09 14.62 7.66
Quick Ratio		 20.49 20.60 13.93 18.07 16.57 12.42 10.66 3.96 14.27 7.43
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -23 -340 -22 -31 -32 279 -42 17 -37
Operating Cash Flow to CapEx		 -580,350.00% 0.00% -99,942.31% -28,477.85% -90,400.00% -517,150.00% 0.00% -188,957.69% 7,010.08% -2,114.73%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.20 0.27
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.23 182.55 105.22
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 0.72 1.81
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,841.79 509.12 201.83
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,841.79 -509.12 -201.83
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -11 -10 305 -17 -16 -20 -21 -55 -2.92 -29
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.23 -10.83 -5.38
Increase / (Decrease) in Invested Capital		 -12 -6.90 308 -13 -4.65 -9.58 -326 -38 13 -9.16
Enterprise Value (EV)		 1,097 1,241 666 436 662 904 1,120 842 664 746
Market Capitalization		 1,471 1,583 984 878 1,067 1,271 1,438 1,204 1,223 1,278
Book Value per Share		 $4.94 $4.51 $4.08 $5.79 $4.48 $3.98 $3.42 $3.51 $6.33 $4.99
Tangible Book Value per Share		 $4.94 $4.51 $4.08 $5.79 $4.48 $3.98 $3.42 $3.32 $6.14 $4.83
Total Capital		 363 332 300 426 390 347 297 307 555 503
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -374 -342 -318 -443 -406 -366 -318 -362 -558 -532
Capital Expenditures (CapEx)		 0.00 0.00 0.03 0.15 0.04 0.01 0.00 0.03 0.72 1.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -11 304 -18 -17 -21 -22 -72 -17 -43
Debt-free Net Working Capital (DFNWC)		 362 331 622 425 389 346 296 289 541 489
Net Working Capital (NWC)		 362 331 622 425 389 346 296 289 541 489
Net Nonoperating Expense (NNE)		 10 10 10 11 10 13 16 -76 -6.68 20
Net Nonoperating Obligations (NNO)		 -374 -342 4.21 -443 -406 -366 -318 -362 -558 -532
Total Depreciation and Amortization (D&A)		 0.17 -1.85 -0.51 -5.17 -2.55 -1.47 -1.18 -0.49 -0.63 -2.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -883.96% -16.80% -32.66%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,533.35% 530.88% 372.73%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,533.35% 530.88% 372.73%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.53) ($0.56) ($0.59) ($0.61) ($0.54) ($0.63) ($0.72) ($0.05) $0.38 ($0.63)
Adjusted Weighted Average Basic Shares Outstanding		 71.01M 65.47M 71.97M 74.96M 85.95M 79.77M 86.68M 87.12M 96.62M 93.23M
Adjusted Diluted Earnings per Share		 ($0.53) ($0.56) ($0.59) ($0.61) ($0.54) ($0.63) ($0.72) ($0.05) $0.38 ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding		 71.01M 65.47M 71.97M 74.96M 85.95M 79.77M 86.68M 87.12M 96.94M 93.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 73.55M 73.59M 73.57M 86.97M 87.04M 87.38M 87.39M 87.76M 100.85M 101.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -30 -32 -34 -36 -42 -47 -80 21 -46
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -981.02% 22.13% -156.57%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -34.85% 38.56% -202.82%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Day One Biopharmaceuticals reported mixed Q4 2024 results. The company continued to invest heavily in R&D as it advances its pipeline, but this drove significant net losses and cash burn. Liquidity remains strong for now, but revenue declined sharply from Q3’s milestone quarter. Retail investors should weigh the progress of pipeline development against rising cash burn and potential dilution.

  • Robust liquidity: cash and short-term investments totaled ~$558 M at Q3-end; current ratio remained healthy at 7.7x in Q4.
  • Gross margin held near 90%, reflecting efficient core operations despite revenue swings.
  • Q3 2024 milestone revenue of $93.8 M highlights strong collaboration potential, boosting 10.4% Q/Q growth in that quarter.
  • Strong balance sheet: market cap of ~$1.28 B supports valuation multiples (EV/Rev ~5.7x, P/Rev ~9.7x) typical for biotech peers.
  • High R&D investment (~$61.8 M in Q4) aligns with pipeline advancement but increases burn – a double-edged driver for long-term value.
  • Sharp revenue decline to $29.2 M in Q4 from $93.8 M in Q3 Q/Q (–68.8%), indicating non-recurring milestone impact rather than sustained growth.
  • Net loss widened to $99.0 M in Q4 (–$0.63 per share) vs. $73.2 M profit in Q3, reflecting increased R&D and lower revenue.
  • Cash burn accelerated: Q4 net cash use of $297.8 M, driven by operating (–$30.0 M) and investing (–$269.6 M) outflows.
  • Free cash flow to firm was negative $36.6 M in Q4, pressuring runway without significant financing.
  • Financing activities provided only ~$1.85 M in Q4, suggesting imminent need for capital raises and potential dilution.
06/25/25 04:48 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Day One Biopharmaceuticals' Financials

When does Day One Biopharmaceuticals' financial year end?

According to the most recent income statement we have on file, Day One Biopharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Day One Biopharmaceuticals' net income changed over the last 2 years?

Day One Biopharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$95.50 million in 2024, falling from -$142.18 million in 2022. The previous period was -$188.92 million in 2023. View Day One Biopharmaceuticals' forecast to see where analysts expect Day One Biopharmaceuticals to go next.

What is Day One Biopharmaceuticals' operating income?
Day One Biopharmaceuticals' total operating income in 2024 was -$217.27 million, based on the following breakdown:
  • Total Gross Profit: $125.88 million
  • Total Operating Expenses: $343.15 million
How has Day One Biopharmaceuticals' revenue changed over the last 2 years?

Over the last 2 years, Day One Biopharmaceuticals' total revenue changed from $0.00 in 2022 to $131.16 million in 2024, a change of 13,116,100,000.0%.

How much debt does Day One Biopharmaceuticals have?

Day One Biopharmaceuticals' total liabilities were at $80.04 million at the end of 2024, a 171.2% increase from 2023, and a 370.2% increase since 2022.

How much cash does Day One Biopharmaceuticals have?

In the past 2 years, Day One Biopharmaceuticals' cash and equivalents has ranged from $85.26 million in 2022 to $230.78 million in 2023, and is currently $124.97 million as of their latest financial filing in 2024.

How has Day One Biopharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Day One Biopharmaceuticals' book value per share changed from 4.51 in 2022 to 4.99 in 2024, a change of 10.4%.


Related Companies

This page (NASDAQ:DAWN) was last updated on 6/25/2025 by MarketBeat.com Staff
From Our Partners
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Crypto Is Pumping Again – Now Comes the Real Opportunity
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Buffett’s $325 Billion Cash Problem — Solved by Gold?
A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...
Golden Portfolio | Sponsored
Trump’s true trade war strategy
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...
Porter & Company | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump c...
Weiss Ratings | Sponsored